Skip to content Skip to footer
Subscribe Now
NEWS

Teva to Acquire Emalex Biosciences for ~$900M

Shots: Teva has entered into a definitive agreement to acquire Emalex Biosciences, incl. its lead asset, ecopipam, expanding its neuroscience pipeline & accelerating Teva’s pivot to growth strategy As per the deal, Teva will acquire Emalex for $700M upfront, & ~$200M in commercial milestones, plus royalties on global net sales of ecopipam, subject to regulatory approval; closing is expected in Q3’26…
April 29, 2026

Read more

NEWS

UCB to Acquire Neurona Therapeutics for ~$1.15B, Expanding into Regenerative Epilepsy Therapies

Shots: UCB has entered into a definitive agreement to acquire Neurona Therapeutics for up to $1.15B, including $650M upfront and up to $500M in potential milestones expected to close by end of Q2’26 The acquisition adds NRTX-1001, an investigational neuronal cell therapy currently in P-I/II study for drug-resistant mesial temporal lobe epilepsy, strengthening UCB’s neuroscience…
April 20, 2026

Read more

NEWS

Eli Lilly to Acquire Centessa Pharmaceuticals in a Deal Valued at ~$7.8B

Shots: Eli Lilly has entered into a definitive agreement to acquire Centessa Pharmaceuticals incl. its asset cleminorexton & ORX142, expanding Lilly's neuroscience portfolio & capabilities into sleep medicine As per the deal, Lilly will acquire all issued & to-be-issued share capital of Centessa (incl. ADSs) for $38/share in cash (~$6.3B upfront), plus a non-transferable CVR of…
March 31, 2026

Read more

INSIGHTS+

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2025 (Part 02)  

Shots:  Novartis led biopharma dealmaking in 2025, executing 23 transactions worth $37.92B with a disciplined, high-impact strategy that balanced scale, science, and strategic fit    Dealmaking was spread across high-conviction areas; neuroscience, cardiovascular disease, immunology, and RNA platforms, combining transformational acquisitions with flexible licensing partnerships to build a future-ready pipeline    Standout transactions (Avidity, Monte…
January 16, 2026

Read more

CXO TALKS

CXO Talks: Vikas Sharma Reveals QurAlis’ Bold Vision for the Future of Neuroscience 

In this episode of CXO Talks, PharmaShots speaks with Vikas Sharma, Chief Business Officer at QurAlis, a biotech company leading the development of precision medicines for neurodegenerative diseases  Vikas discusses the company’s FlexASO platform, a next-generation RNA-targeting technology that tackles the root causes of neurological diseases  Vikas also highlights QurAlis’ lead candidates, QRL-201 and QRL-101,…
November 10, 2025

Read more

NEWS

Novartis to Acquire Avidity Biosciences for ~$12B, Boosting its Neuroscience Pipeline

Shots: Novartis has agreed to acquire Avidity Biosciences, strengthening its neuroscience pipeline with Avidity’s Antibody Oligonucleotide Conjugates (AOCs) platform & 3 late-stage programs As per the deal, Novartis will acquire Avidity for $72/share, valuing the company at ~$12B with an enterprise value of ~$11B; closing expected in H1’26 Before the merger, Avidity will transfer its early-stage precision…
October 27, 2025

Read more

AbbVie & ADARx Pharmaceuticals
NEWS

AbbVie Partners with ADARx Pharmaceuticals to Develop siRNA Therapies Across Multiple Disease Areas

Shots: AbbVie has entered into collaboration & license option agreement with ADARx to develop siRNA therapeutics across multiple disease areas, incl. neuroscience, immunology & oncology, leveraging ADARx's RNA tech As per the deal, ADARx will receive $335M upfront & will be eligible to receive several billion in additional contingent payments incl. option fees, milestones, plus tiered royalties…
May 15, 2025

Read more

Netramark & Worldwide Clinical Trials
NEWS

NetraMark Join Forces with Worldwide Clinical Trials to Redefine Clinical Trial Design Using NetraAI Platform

Shots: NetraMark and Worldwide Clinical Trials have entered into a global agreement to utilize NetraMark’s NetraAI platform to advance clinical trial design As per the deal, NetraAI will initially support P-II neuroscience & oncology trials, plus select P-III studies conducted by Worldwide, with broader access extended to Worldwide’s sponsors across all therapeutic areas & trial…
April 4, 2025

Read more

VIEWPOINTS_Angela Cacace_2024
VIEWPOINTS

Transformative Neurodegenerative Disorder Care: Angela Cacace in Conversation with PharmaShots

Shots: Angela Cacace Sr. VP, of Neuroscience and Platform Biology at Arvinas, shares insights from the preclinical trials evaluating ARV-102 for treatment of neurodegenerative diseases and dosing people with the first oral formulation (ARV-102) to treat neurodegenerative diseases ARV-102, a novel oral PROTAC® protein degrader, is designed to cross the blood-brain barrier and target leucine-rich repeat kinase…
April 29, 2024

Read more

Viewpoints_Karl Bradshaw
VIEWPOINTS

Karl Bradshaw, VP of Corporate Development at Metabolon, Shares Insights on the Partnership with The University of Oxford Parkinson’s Disease Centre

Shots: Karl spoke on Metabolon’s partnership with the University of Oxford Parkinson’s Disease Centre (OPDC) to identify new metabolomic biomarkers for the advancement of Parkinson’s research  Karl also talked about the metabolomic changes which occur in Parkinson’s disease and how Metabolon will support OPDC's mission to improve research and understanding of the biology of early…
September 21, 2022

Read more

Load more